Asymmetric anti-CLL-1xCD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine releaseJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62023-10-176OAAI
PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cellsMOLECULAR THERAPYIF122022-02-0143OAAI
未登录.png){kind=icon}
未登录
